Investors have endured a lot in the past year with economic issues, geopolitical tensions, and a pandemic that isn't entirely over yet. Further, although the market is performing better in 2023, there could be a recession later this year, according to the U.S. Federal Reserve.

In this shaky environment, it helps to invest in steady, dividend-paying companies that perform decently even when the economy tanks. Let's consider the case of Bristol Myers Squibb (NYSE: BMY). There is a lot to like about this company, particularly for value investors, making it a buy this May. 

The best pharmaceutical companies generally have deep pipelines that allow them to launch new products regularly and keep their revenue and earnings flowing in the right direction over the long run. This description applies to Bristol Myers Squibb. The company's vast pipeline with several dozen clinical trials yields positive clinical and regulatory wins often enough.

Continue reading

Source Fool.com